Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - queratite - oftalmológicos - tratamento do defeito epitelial moderado (persistente epitelial) ou grave (úlcera da córnea) em adultos.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacinas - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porcos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacinas - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - imunológicos para leporidae - coelhos - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infecções respiratórias do vírus sincitial - vacinas - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. veja as seções 4. 2 e 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

biopartners gmbh - recombinant human interferon alfa-2a - hepatite c, crônica - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

gsk vaccines s.r.l. - exterior membrana das vesículas de neisseria meningitidis do grupo b (tensão nz 98/254), recombinante neisseria meningitidis do grupo b fhbp proteína de fusão, recombinante neisseria meningitidis do grupo b, nada de proteínas, recombinação de neisseria meningitidis do grupo b nhba proteína de fusão - meningite, meningococo - vacinas meningocócicas - imunização ativa contra a doença invasiva causada por cepas neisseria meningitidis serogroup-b.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

pharming group n.v. - humano recombinante de inibidor de c1 - angioedemas, hereditário - drugs used in hereditary angioedema, other hematological agents - ruconest é indicado para o tratamento de ataques de angioedema agudo em adultos com angioedema hereditário (hae) devido à deficiência de inibidor de esterase c1.

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

biosintÉtica farmacÊutica ltda - imunomodulador